Thérapie génique : 3 millions d’euros pour AAVLife

Thérapie génique : 3 millions d’euros pour AAVLife. Bpifrance 12 février 2015


Gene therapy for FA is blooming, yesterday knew the good news of the major strategic collaboration between Sanofi-Genzyme and Voyager Therapeutics, today it has known the news of a new economic aportacion to AAVLIFE project, which develops a gene therapy with AAV vectors for FA, targeted to the heart


Bpifrance investit, via le Fonds Biothérapies innovantes et Maladies rares, 3 millions d’euros dans la société de thérapie génique AAVLife. Une opération va lui permettre de faire progresser la thérapie génique pour le traitement des cardiomyopathies liées à l’ataxie de Friedreich.

Related news:


AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.

AAVLife Raises $12 Million in Series A Financing to Advance Gene Therapy for Friedreich’s Ataxia

Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders

Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders. (BUSINESS WIRE) February 11, 2015.

Sanofi embarks on an $845M gene therapy R&D odyssey with Voyager


Up to $845 Million Collaboration to Support Development, Expansion and Commercialization of Voyager’s Novel CNS Product Pipeline


Press Release (PDF): Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders.